CV Sciences (CVSI) Change in Receivables (2013 - 2026)
CV Sciences (CVSI) reported Change in Receivables of -$22000.0 for Q1 2026, up 78.0% on a YoY basis from -$12359.6 in Q1 2025, and down 466.67% sequentially from $6000.0 in Q4 2025.
CV Sciences (CVSI) Change in Receivables (2013 - 2026) Analysis & Trends
CV Sciences (CVSI) has 14 years of Change in Receivables data on file, last reported at -$22000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 78.0% year-over-year to -$22000.0; the trailing twelve-month figure through Mar 2026 stood at -$46000.0 (up 46.51% YoY), and the FY2025 full-year result was -$124000.0, down 247.62% from the prior year.
- Change in Receivables retreated to -$22000.0 in Q1 2026, from $6000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $130000.0 in Q2 2024 to a low of -$1.1 million in Q1 2022.
- A 5-year average of -$87000.0 and a median of -$22000.0 in 2026 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables sank 724.06% in 2022 and soared 382.61% in 2024, its largest moves.
- Tracing CVSI's Change in Receivables over 5 years: stood at $107000.0 in 2022, then plunged by 332.71% to -$249000.0 in 2023, then surged by 141.37% to $103000.0 in 2024, then sank by 94.17% to $6000.0 in 2025, then sank by 466.67% to -$22000.0 in 2026.
- Business Quant data shows CVSI's Change in Receivables at -$22000.0 in Q1 2026, $6000.0 in Q4 2025, and -$142000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -22,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22,000.00 |
| Mar 31, 2026 | -22,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | -142,000.00 |
| Sep 30, 2025 | -142,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Sep 30, 2024 | -219,000.00 |
| Sep 30, 2024 | -219,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | -249,000.00 |
| Dec 31, 2023 | -249,000.00 |